NI201000044A - Bromhidrato de bupropión y aplicaciones terapéuticas - Google Patents

Bromhidrato de bupropión y aplicaciones terapéuticas

Info

Publication number
NI201000044A
NI201000044A NI201000044A NI201000044A NI201000044A NI 201000044 A NI201000044 A NI 201000044A NI 201000044 A NI201000044 A NI 201000044A NI 201000044 A NI201000044 A NI 201000044A NI 201000044 A NI201000044 A NI 201000044A
Authority
NI
Nicaragua
Prior art keywords
bupropion
bromhydrate
therapeutic applications
treatment
conditions
Prior art date
Application number
NI201000044A
Other languages
English (en)
Inventor
Jackson Graham
Oberegger Werner
Maes Paul
Ashty Saleh Mohammad
Original Assignee
Biovail Laboratories Int S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40521541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201000044(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail Laboratories Int S R L filed Critical Biovail Laboratories Int S R L
Publication of NI201000044A publication Critical patent/NI201000044A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Abstract

Formulaciones de hidrobromuro de Bupropion, así como su uso para el tratamiento de condiciones como se describen.
NI201000044A 2007-10-31 2010-03-26 Bromhidrato de bupropión y aplicaciones terapéuticas NI201000044A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/930,644 US7645802B2 (en) 2005-06-27 2007-10-31 Bupropion hydrobromide and therapeutic applications

Publications (1)

Publication Number Publication Date
NI201000044A true NI201000044A (es) 2010-09-29

Family

ID=40521541

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000044A NI201000044A (es) 2007-10-31 2010-03-26 Bromhidrato de bupropión y aplicaciones terapéuticas

Country Status (13)

Country Link
US (3) US7645802B2 (es)
EP (1) EP2214650A2 (es)
JP (1) JP2011500865A (es)
KR (1) KR20100077182A (es)
CN (1) CN101903016A (es)
AU (1) AU2008320915B2 (es)
CA (1) CA2699588A1 (es)
CO (1) CO6270385A2 (es)
MX (1) MX2010003872A (es)
NI (1) NI201000044A (es)
RU (1) RU2485942C2 (es)
WO (1) WO2009056550A2 (es)
ZA (1) ZA201003036B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5095615B2 (ja) 2005-06-27 2012-12-12 バリアント・インターナショナル・（バルバドス）・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ ブプロピオン塩の放出調整製剤
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
US7645802B2 (en) * 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
US8349900B2 (en) * 2008-08-07 2013-01-08 Valeant International Bermuda Bupropion hydrobromide polymorphs
EP2326351B1 (en) 2008-08-19 2017-12-27 Nektar Therapeutics Conjugates of small-interfering nucleic acids
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
ITMI20090190A1 (it) * 2009-02-13 2010-08-14 Dipharma Francis Srl Forma cristallina di bupropione bromidrato
US20120076865A1 (en) 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
KR101873075B1 (ko) * 2010-08-18 2018-06-29 에보니크 룀 게엠베하 하나 이상의 알긴산 염을 포함하는 위 내성 제약 또는 건강기능식품 제제
EP2601973A1 (en) * 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
US20150157575A1 (en) * 2013-12-10 2015-06-11 Forest Laboratories Holdings Ltd. Pharmaceutical Formulations Comprising Vilazodone
JP6695337B2 (ja) * 2014-11-26 2020-05-20 レーム・ゲーエムベーハーＲｏｅｈｍ ＧｍｂＨ エタノールの影響に対する耐性を有する医薬品組成物または栄養機能食品組成物
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CA2978556C (en) * 2015-03-02 2022-02-15 Graphene 3D Lab Inc. Thermoplastic composites comprising water-soluble peo graft polymers useful for 3-dimensional additive manufacturing
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
AU2020257625A1 (en) 2019-04-17 2021-11-04 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
MEP3608A (en) * 2003-08-08 2011-05-10 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
US7645802B2 (en) 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US7671094B2 (en) 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
JP5095615B2 (ja) 2005-06-27 2012-12-12 バリアント・インターナショナル・（バルバドス）・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ ブプロピオン塩の放出調整製剤
US20070184115A1 (en) * 2005-12-30 2007-08-09 Biovail Laboratories International S.R.L. Modified release formulations of tramadol and uses thereof
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US8349900B2 (en) * 2008-08-07 2013-01-08 Valeant International Bermuda Bupropion hydrobromide polymorphs

Also Published As

Publication number Publication date
CO6270385A2 (es) 2011-04-20
US7645802B2 (en) 2010-01-12
AU2008320915B2 (en) 2013-05-09
US20100255094A1 (en) 2010-10-07
RU2485942C2 (ru) 2013-06-27
MX2010003872A (es) 2010-04-27
CN101903016A (zh) 2010-12-01
WO2009056550A2 (en) 2009-05-07
JP2011500865A (ja) 2011-01-06
KR20100077182A (ko) 2010-07-07
RU2010116863A (ru) 2011-12-10
EP2214650A2 (en) 2010-08-11
AU2008320915A1 (en) 2009-05-07
CA2699588A1 (en) 2009-05-07
US20130266650A1 (en) 2013-10-10
US20080274181A1 (en) 2008-11-06
WO2009056550A3 (en) 2009-06-18
ZA201003036B (en) 2011-07-27

Similar Documents

Publication Publication Date Title
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
CL2008001114A1 (es) Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras.
CL2015002519A1 (es) Composiciones antimicrobiales y procedimientos de uso relacionados.
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CR11731A (es) Composiciones y procedimientos para su preparación y uso
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2008002893A1 (es) Compuestos derivados de n-fenil-(piridin-3-il) acetamida sustituidas; composicion farmaceutica; procedimiento de preparacion; y su uso para prevenir o tratar el cancer.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
UY32659A (es) Pirazinilpirazoles
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
PA8784301A1 (es) Oxazolidinonas sustituidas y su uso
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.